Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Alterity Therapeutics Ltd(ATHE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ATHE
09/25/2026: ATHE (1-star) is currently NOT-A-BUY. Pass it for now.
Alterity Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule treatments for neurodegenerative conditions like Multiple System Atrophy. Its primary strength lies in its proprietary iron-chaperone technology, which offers a distinct approach to managing neurodegeneration. The investment story centers on the potential for its lead asset, ATH434, to secure regulatory approval and fulfill an unmet medical need in orphan diseases. However, investors must consider the high risks of a pre-revenue, single-asset pipeline, including clinical trial outcomes, regulatory challenges, and the potential for shareholder dilution. The stock best suits risk-tolerant investors who monitor clinical trial updates and potential strategic partnership developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | It offers high-upside potential if trials succeed, but lacks the established growth metrics traditional growth investors require. |
| Momentum investor | Mixed fit | The stock can exhibit high momentum during trial updates, but requires a positive upturn signal to be viable. |
| Value investor | Weak fit | As a pre-revenue clinical firm, it lacks earnings or assets to support a traditional value-based valuation. |
| Dividend investor | Weak fit | The company does not pay dividends and requires capital to fund operations. |
| Low-risk investor | Weak fit | The high volatility and binary nature of clinical outcomes make this unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience sharp price swings based on trial data news. |
| Valuation risk | High | Valuation is speculative and heavily dependent on the eventual successful commercialization of ATH434. |
| Competition risk (Parkinsonian treatments) | Medium / high | The company faces stiff competition from established neurology players with deep resources. |
| Business quality | Medium | The company is early-stage with a focused but unproven pipeline. |
| Dividend income | Low / none | There is no income stream or prospect of dividends in the near term. |
| Execution risk | High | The primary risk is the successful execution of clinical trials and achieving regulatory endpoints. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -34.27% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 68.65M USD | Price to earnings Ratio - | 1Y Target Price 13.25 |
Price to earnings Ratio - | 1Y Target Price 13.25 | ||
Volume (30-day avg) 17.8K shares | Beta -0.04 | 52 Weeks Range 2.66 - 5.89 | Updated Date 09/24/2026 |
52 Weeks Range 2.66 - 5.89 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.01 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical R&D | Advancement of ATH434 for neurological conditions. | The company is a 'bet' on the successful development and approval of its drugs. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40.42M | Price to Sales(TTM) 19.02 |
Enterprise Value 40.42M | Price to Sales(TTM) 19.02 | ||
Enterprise Value to Revenue 113.99 | Enterprise Value to EBITDA 0.75 | Shares Outstanding 18.21M | Shares Floating 14.28M |
Shares Outstanding 18.21M | Shares Floating 14.28M | ||
Percent Insiders - | Percent Institutions 2.07 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Alterity Therapeutics Ltd
Exchange NASDAQ | Headquarters Melbourne, VIC, Australia | ||
IPO Launch date 2002-09-05 | CEO & Director Dr. David A. Stamler M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://alteritytherapeutics.com |
Full time employees 11 | Website https://alteritytherapeutics.com | ||
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.